- Home
- SQFT vs GOVX Comparison
SQFT vs GOVX Comparison
Compare SQFT & GOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SQFT | GOVX |
|---|---|---|
| Founded | 1999 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2M | 3.8M |
| IPO Year | 2005 | 1996 |
Fundamental Metrics
Financial Performance| Metric | SQFT | GOVX |
|---|---|---|
| Price | $1.35 | $0.46 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $1.00 |
| AVG Volume (30 Days) | 490.3K | ★ 668.0K |
| Earning Date | 05-13-2026 | 04-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $16,814,708.00 | $2,489,145.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.19 | $0.12 |
| 52 Week High | $10.47 | $4.40 |
Technical Indicators
Market Signals| Indicator | SQFT | GOVX |
|---|---|---|
| Relative Strength Index (RSI) | 36.66 | 29.17 |
| Support Level | $1.32 | $0.14 |
| Resistance Level | $2.37 | $0.86 |
| Average True Range (ATR) | 0.17 | 0.07 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 13.48 | 3.65 |
Price Performance
Historical ComparisonAbout SQFT Presidio Property Trust Inc.
Presidio Property Trust Inc is an internally managed, diversified REIT with holdings in model home properties which are triple-net leased to homebuilders, office, industrial, and retail properties. Presidio's model homes are leased to homebuilders located in Arizona, Illinois, Texas, Wisconsin, and Florida. The office, industrial and retail properties are located in Colorado, with properties also located in Maryland, North Dakota, Texas, and Southern California.
About GOVX GeoVax Labs Inc.
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. The company is focused on the advancement of GEO-MVA, a Modified Vaccinia Ankara (MVA) vaccine candidate for mpox, smallpox, and other poxviruses. Its flagship clinical program in oncology is Gedeptin, a novel oncolytic solid tumor gene-directed therapy, which recently completed a multicenter Phase 1/2 clinical trial for head and neck cancers. The company is also developing GEO-CM04S1, a next-generation multi-antigen COVID-19 vaccine, which is currently being evaluated in two Phase 2 clinical trials.